Summary of Key Points WHO Position Paper on Vaccines against Hepatitis E Virus(HEV) May 2015
|
|
- Antony Blair
- 6 years ago
- Views:
Transcription
1 Summary of Key Points WHO Position Paper on Vaccines against Hepatitis E Virus(HEV) May
2 Background l Hepatitis E Virus (HEV): leading cause of acute viral hepatitis in developing countries. l Genotypes 1 and 2: Primarily infect humans, mainly male young adults Annually cause 20.1 M infections, 3.4 M symptomatic cases, deaths, 3000 stillbirths. Genotype 1 is: most prevalent; widely found in Asia and Africa; causes high mortality in pregnant women, and poor fetal outcomes Genotype 2 cases in Mexico, Nigeria, Namibia l Genotypes 3 and 4: Primarily infect mammalian animals; occasional transmission to humans Genotype 3 cases almost entirely in developing countries Genotype 4 human cases mainly in mainland China and Taiwan 2
3 Background l HEV transmission: Sporadic disease in endemic countries. Periodic large epidemics due to contamination of water sources. Greatest disease burden in developing areas where clean water is scarce. l Treatment: There are no WHO guidelines on treatment of Hepatitis E. Treatment is generally supportive. 3
4 Vaccines l HEV 239 Vaccine: Hecolin Experimental vaccine at clinical trial stage in humans that has been developed and manufactured. Currently only licensed in China Licensed for use in people years of age who are at high risk for HEV infection based on occupation/lifestyle Those involved in animal husbandry, food handling, students, army personnel, young women, travellers 4
5 Immunogenicity and Effectiveness l Highly immunogenic Almost all recipients seroconverted after 3 doses on a 0,1,6 month schedule. l Efficacy rate: High efficacy rate in healthy adults between years of age in China, primarily against Genotype 4. Limited data on protection against Genotype 1 No data on protection against Genotypes 2 and 3 However, there is data to show expected protection against all 4 genotypes. 5
6 WHO Position l Hepatitis E recognized as an important public health problem in developing countries Especially among special populations: pregnant women, displaced individuals living in camps, outbreak situations. l In the absence of sufficient information, the WHO does not: make a recommendation on the introduction of the vaccine for routine use in national programmes in populations where epidemic and sporadic hepatitis E disease is common. However, national authorities may decide to use the vaccine based on the local epidemiology. Recommend routine use of vaccine in the following groups in endemic areas: Children below age of 16 years Pregnant women Patients with chronic liver disease Patients on organ transplant wait lists Travellers 6
7 WHO Position l In outbreak situations (high risk of Hep E) WHO recommends: Considering use of HEV 239 vaccine to mitigate risk of Hep E outbreaks for high risk groups: Pregnant women Travellers Health and humanitarian relief workers Evaluate risk and benefit of vaccination on an individual basis l To address information gaps WHO recommends: Pre-emptive design of research protocol to study vaccine safety and immunogenicity in outbreak situations among high risk groups. 7
8 Information Gaps l Incidence and mortality of the Hep E disease in general and in special populations; l Immunogenicity of HEV 239: outside the age range in populations at higher risk for hep E disease E.g. with pre-existing liver disease or immunosuppressive conditions in pregnant women after SC vs. ID administration on an accelerated schedule. 8
9 Information Gaps l Efficacy of HEV 239: against disease caused by genotypes 1, 2 and 3; long term efficacy, duration of protection with fewer than 3 doses or shorter intervals between doses; need and timing of potential booster dose l Effectiveness of HEV 239 l Cost effectiveness of vaccine programme in outbreak settings 9
10 For more information on the WHO HEV position paper, please visit the WHO website: positionpapers
Hepatitis E FAQs for Health Professionals
Hepatitis E FAQs for Health Professionals Index of Questions ± Overview and Statistics What is Hepatitis E? How common is Hepatitis E in the United States? Where is Hepatitis E most common? Are there different
More informationHepatitis E in developing countries
Hepatitis E in developing countries Hepatitis E in developing countries Rakesh Aggarwal Department of Gastroenterology Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India Forms Epidemic
More informationHepatitis E in South Africa. Tongai Maponga
Hepatitis E in South Africa Tongai Maponga 7th FIDSSA CONGRESS 2017 This is what usually comes to mind History of hepatitis E virus An ET-NANB hepatitis virus later named HEV was first suspected in 1980.
More informationEpidemiological profiles of viral hepatitis in Italy Effects of migration
Epidemiological profiles of viral hepatitis in Italy Effects of migration Hepatitis A and E T. Santantonio UOC di Malattie Infettive Università degli Studi di Foggia Azienda Ospedaliero-Universitaria Ospedali
More informationViral Hepatitis in Reproductive Health
Viral Hepatitis in Reproductive Health Training Course in Sexual and Reproductive Health Research Geneva 2010 Dr José M Bengoa Dr Pierre Jean Malè Consultants Division of Gastroenterology and Hepatology
More informationTravel. Program Management. Schedule
Program Management 69_4 YF (yellow fever) vaccine should be offered to all travellers to and from at-risk areas, unless they belong to the group of individuals for whom YF vaccination is contraindicated.
More informationHepatitis E Virus Infection. Disclosures
Hepatitis E Virus Infection Simona Rossi, MD Associate Chair, Division of Hepatology Einstein Medical Center Philadelphia Consultant for BMS Speaker for Gilead Disclosures I have no conflicts to report
More informationEpidemiology Update Hepatitis A
December 2011 Epidemiology Update Hepatitis A Hepatitis A Key Points Between 2000 and 2010, 209 cases of hepatitis A were reported in Hennepin County residents. This represents 30% of the cases reported
More informationResearch article Acute viral hepatitis morbidity and mortality associated with hepatitis E virus infection: Uzbekistan surveillance data
Acute Hepatitis E Infection In A Visitor To Louisiana.(Case Report): An Article From: Southern Medical Journal [HTML] [Digital] By James Edward, Jr. Walker;Todd Martin Brown;Thomas Lanier Hagood;William
More informationAre 10-year booster doses of yellow fever vaccine necessary? Peter Teitelbaum, MD Committee to Advise on Tropical Medicine and Travel (CATMAT)
Are 10-year booster doses of yellow fever vaccine necessary? Peter Teitelbaum, MD Committee to Advise on Tropical Medicine and Travel (CATMAT) Disclosure of Potential for Conflict of Interest Peter Teitelbaum,
More informationHow to talk about typhoid: menu of messages
How to talk about typhoid: menu of messages PATH/Rocky Prajapati The more we talk about typhoid, the better we ll be able to prioritize it. These messages were developed for use by anyone interested in
More informationSummary of Key Points. WHO Position Paper on Vaccines against Hepatitis B, July 2017
Summary of Key Points WHO Position Paper on Vaccines against Hepatitis B, July 2017 1 Background l HBV is transmitted by exposure of mucosal membranes or non-intact skin to infected blood, saliva, semen
More informationSandi Mitchell Nurse Educator Clinical Prevention Services BCCDC
Sandi Mitchell Nurse Educator Clinical Prevention Services BCCDC sandi.mitchell@bccdc.ca Hepatitis A, B and C Testing Transmission Treatment What Is Hepatitis? Hepatitis means inflammation of the liver
More informationIntroduction. Infections acquired by travellers
Introduction The number of Australians who travel overseas has increased steadily over recent years and now between 3.5 and 4.5 million exits are made annually. Although many of these trips are to countries
More informationEmerging TTIs How Singapore secure its blood supply
Emerging TTIs How Singapore secure its blood supply Ms Sally Lam Acting Division Director I Blood Supply Management I Blood Services Group I Health Sciences Outline Risk Mitigation Strategies to secure
More informationUses and Misuses of Viral Hepatitis Testing. Origins of Liver Science
Uses and Misuses of Viral Hepatitis Testing Richard S Lang, MD, MPH, FACP Chairman, Preventive Medicine Vice-Chair, Wellness Institute Raul J Seballos, MD, FACP Vice-Chair, Preventive Medicine Wellness
More informationAdverse Event GACVS. Global Advisory Committee on Vaccine Safety, 910 June 2005
Adverse Event The Committee considered the decision taken by the Government of Japan on 30 May 2005 to suspend routine vaccination with the mouse brainderived Japanese encephalitis (JE) vaccine currently
More informationVIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES IN THE AFRICAN REGION. Report of the Secretariat. CONTENTS Paragraphs BACKGROUND...
8 April 2014 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH PROGRAMME SUBCOMMITTEE Sixty-fourth session Brazzaville, Republic of Congo, 9 11 June 2014 Provisional agenda item 6 VIRAL HEPATITIS: SITUATION
More informationTravel and transport risk assessment. Preparedness for potential outbreak of
Travel and transport risk assessment Preparedness for potential outbreak of Ebola Interim virus guidance disease: for A public framework health for authorities and action the transport in the Western sector
More informationVIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES IN THE AFRICAN REGION. Report of the Secretariat. CONTENTS Paragraphs BACKGROUND...
5 November 2014 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Sixty-fourth session Cotonou, Republic of Benin, 3 7 November 2014 Provisional agenda item 11 VIRAL HEPATITIS: SITUATION ANALYSIS AND PERSPECTIVES
More informationHepatitis B vaccine: long-term efficacy, booster policy, and impact of HBV mutants on hepatitis B vaccination programmes
Hepatitis B vaccine: long-term efficacy, booster policy, and impact of HBV mutants on hepatitis B vaccination programmes VHPB meeting, Seville, 11-12 March 2004 Immunization programmes Programmes protect
More informationYellow fever. Key facts
From: http://www.who.int/en/news-room/fact-sheets/detail/yellow-fever WHO/E. Soteras Jalil Yellow fever 14 March 2018 Key facts Yellow fever is an acute viral haemorrhagic disease transmitted by infected
More informationMedia centre. WHO Hepatitis B. Key facts. 1 of :12 AM.
1 of 5 2013-08-02 7:12 AM Media centre Hepatitis B Share Print Fact sheet N 204 Updated July 2013 Key facts Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic
More informationHEPATITIS VIRUSES. Other causes (not exclusively hepatitis v.)also called sporadic hepatitis: HEPATITIS A(infectious hepatitis)
Dept.of Microbiology/Virology Assist.prof. Shatha F. Abdullah HEPATITIS VIRUSES Medically important hepatitis v. (liver)are: 1.HAV 2.HBV 3.HCV 4.HDV 5.HEV 6.HGV Other causes (not exclusively hepatitis
More informationViral Hepatitis. WHO Regional Office for Europe July 2013
Viral Hepatitis WHO Regional Office for Europe July 2013 What is Hepatitis? Hepatitis is a viral infection that causes inflammation of the liver There are five main types of viral hepatitis: A, B, C, D,
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091650 Age 49 Years Gender Male 29/8/2017 120000AM 29/8/2017 100248AM 29/8/2017 105306AM Ref By Final HEATITIS, VIRAL, COMREHENSIVE ANEL HEATITIS A ANTIBODY (ANTI
More informationBelow you will find information about diseases, the risk of contagion, and preventive vaccinations.
Vaccinations Below you will find information about diseases, the risk of contagion, and preventive vaccinations. DTP - Diphtheria Tetanus Polio Yellow fever Hepatitis A Typhoid fever Cerebrospinal meningitis
More informationErratum to: A systematic review of the epidemiology of hepatitis E virus in Africa
Kim et al. BMC Infectious Diseases (2017) 17:187 DOI 10.1186/s12879-017-2274-3 ERRATUM Erratum to: A systematic review of the epidemiology of hepatitis E virus in Africa Open Access Jong-Hoon Kim 1*, Kenrad
More informationPrevention and control of hepatitis B and C in the European Region of WHO
Prevention and control of hepatitis B and C in the European Region of WHO Viral Hepatitis Prevention Board Dr Nedret Emiroglu WHO Regional Office for Europe Burden of viral hepatitis in the European Region
More informationInfluenza. Influenza vaccines (WHO position paper) Weekly Epid. Record (2005, 80: ) 287
Program Management 82_19 SAGE encouraged all countries to consider their preparedness for a potential influenza pandemic, recognizing that it would occur before strain-specific vaccine can be made in significant
More informationPolio Vaccine. By: Lia Schmitz, Pharm.D. Poliomylitis is a viral infection for which vaccination is generally given
Polio Vaccine By: Lia Schmitz, Pharm.D. Poliomylitis is a viral infection for which vaccination is generally given to infants and small children, and to people planning to travel to countries in which
More informationHEPATITIS B INFECTION and Pregnancy. Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011
HEPATITIS B INFECTION and Pregnancy Caesar Mensah Communicable Diseases & Infection Control Specialist, UK June 2011 HEPATITIS B 26/07/2011 What is Hepatitis B? It is inflammation (infection) of the liver
More informationGlobal updates on avian influenza and tools to assess pandemic potential. Julia Fitnzer Global Influenza Programme WHO Geneva
Global updates on avian influenza and tools to assess pandemic potential Julia Fitnzer Global Influenza Programme WHO Geneva Pandemic Influenza Risk Management Advance planning and preparedness are critical
More informationin control group 7, , , ,
Q1 Rotavirus is a major cause of severe gastroenteritis among young children. Each year, rotavirus causes >500,000 deaths worldwide among infants and very young children, with 90% of these deaths occurring
More informationUniversity of Louisville Campus Health Services 401 East Chestnut Street Suite110 P: F:
University of Louisville Campus Health Services 401 East Chestnut Street Suite110 P: 502-852-2708 F: 502-852-0660 hlthoff@louisville.edu Training Objectives Understand the OSHA Bloodborne Pathogens Regulation
More informationHepatitis E Virus Update December 2014
655 West 12th Avenue Vancouver, BC V5Z 4R4 Tel 604.707.2400 Fax 604.707.2516 www.bccdc.ca Hepatitis E Virus Update December 2014 What is hepatitis E Virus? Hepatitis E Virus (HEV) was first identified
More informationSeries of 2 doses, 6-12 months apart. One dose is 720 Elu/0.5ml (GSK) or 25 u/0.5 ml (Merck)
UTAH PREVENTIVE CARE RECOMMENDATIONS Adult - Ages 19 and Above IMMUNIZATIONS CONTENTS: General Instructions Hepatitis A Hepatitis B Human Papilloma Virus Influenza Meningococcal A, C, Y, W (MCV4) Meningococcal
More informationHepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY November 2011
Viral Hepatitis Prevention Board Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? MILAN, ITALY 17-18 November 2011 Objectives To review long-term efficacy of hepatitis B vaccine
More informationFact sheet. Yellow fever
Fact sheet Key facts is an acute viral haemorrhagic disease transmitted by infected mosquitoes. The yellow in the name refers to the jaundice that affects some patients. Up to 50% of severely affected
More informationNalini Brown Nurse Manager/Travel Health Specialist London Travel Clinic
Nalini Brown Nurse Manager/Travel Health Specialist nalini.brown@londontravelclinic.co.uk London Travel Clinic TOPICS Why do a travel risk assessment? Vaccines what s new? Advising patients when there
More informationEvidence to Recommendation Table 1
Evidence to Recommendation Table 1 Questions: Can the duration of the entire course and/or the number of doses administered of current PEP regimens be reduced while maintaining immunogenicity and effectiveness?
More informationSIXTY-SECOND WORLD HEALTH ASSEMBLY A62/22 Provisional agenda item April Viral hepatitis. Report by the Secretariat
SIXTY-SECOND WORLD HEALTH ASSEMBLY A62/22 Provisional agenda item 12.17 16 April 2009 Viral hepatitis Report by the Secretariat THE DISEASES AND BURDEN 1. The group of viruses that cause acute and/or chronic
More informationPromoting hepatitis B vaccination
Promoting hepatitis B vaccination Introduction Hepatitis B is a serious blood borne infection that can exacerbate hepatitis C infection, can cause serious liver damage and sometimes results in death. Hepatitis
More informationHepatitis A and Hepatitis E
Hepatitis A and Hepatitis E Luis S. Marsano, MD Professor of Medicine Division of Gastroenterology, Hepatology & Nutrition University of Louisville and Louisville VAMC 2011 Viruses that cause Hepatitis
More informationTest Name Results Units Bio. Ref. Interval
LL - LL-ROHINI (NATIONAL REFERENCE 135091608 Age 26 Years Gender Female 30/8/2017 92900AM 30/8/2017 94717AM 31/8/2017 90216AM Ref By Final HEATITIS ACUTE VIRUS CONFIRMATION HEATITIS A ANTIBODY (ANTI HAV),
More informationINTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION a Society that includes Basic Science, the Failing Heart, and Advanced Lung Disease
International Society of Heart and Lung Transplantation Advisory Statement on the Implications of Pandemic Influenza for Thoracic Organ Transplantation This advisory statement has been produced by the
More informationEpidemiology of hepatitis E infection in Hong Kong
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES Epidemiology of hepatitis E infection in Hong Kong DPC Chan *, KCK Lee, SS Lee K e y M e s s a g e s 1. The overall anti hepatitis E virus (HEV) seropositivity
More informationHepatitis A Virus Infections
Hepatitis A Virus Infections Robert L. Brawley, MD, MPH, FSHEA Chief, Infectious Disease Branch Division of Epidemiology and Health Planning Kentucky Department for Public Health Objectives Discuss the
More informationDisease Prevention, Detection & Response During Public Health Emergencies
Centers for Disease Control and Prevention Disease Prevention, Detection & Response During Public Health Emergencies Tom Frieden, MD, MPH Director, Centers for Disease Control and Prevention Global Disaster
More informationSummary of the October 2017 meeting of the Strategic Advisory Group of Experts on Immunization
Summary of the October 2017 meeting of the Strategic Advisory Group of Experts on Immunization The Strategic Advisory Group of Experts (SAGE) on Immunization 1 met on 17-19 October 2017 in Geneva, Switzerland.
More informationEpidemiology of HAV, HDV and HEV in Belgium
Epidemiology of HAV, HDV and HEV in Belgium Prof. Dr. Steven Van Gucht National Reference Centre of Hepatitis Viruses B, C, D and E Viral Diseases Scientific Institute of Public Health (WIV-ISP) Brussels
More informationImmunization Guidelines For the Use of State Supplied Vaccine July 1, 2011
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationIMMUNIZATION IN CHILDREN WITH CANCER
SIOP PODC Supportive Care Education Presentation Date: 05 th September 2014 Recording Link at www.cure4kids.org: http://www.cure4kids.org/ums/home/conference_rooms/enter.php?room=p2xokm5imdj Email: ahmed.naqvi@sickkids.ca
More informationPneumococcal Vaccines. What s right for your clients?
Pneumococcal Vaccines What s right for your clients? Vaccines Available - Pneumovax 23 A pneumococcal polysaccharide vaccine that includes 23 purified capsular polysaccharide antigens Vaccines Available
More informationHEPATITIS B WHAT YOU NEED TO KNOW ARE YOU SURE YOU USE THE RIGHT MEASURES TO PROTECT YOURSELF AGAINST HEPATITIS B?
HEPATITIS B WHAT YOU NEED TO KNOW ARE YOU SURE YOU USE THE RIGHT MEASURES TO PROTECT YOURSELF AGAINST HEPATITIS B? GET INFORMED! GET VACCINATED! GET PROTECTED! HEPATITIS VACCINE DID YOU KNOW THAT? Hepatitis
More informationHistory and aims of immunisation. Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8
History and aims of immunisation Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8 Objectives To examine the history of immunisation To explain the aim of immunisation To develop
More informationIdentification and management of chronic viral hepatitis in Russia
Technical Viral Hepatitis Prevention Board Meeting IDENTIFICATION AND MANAGEMENT OF PERSONS WITH CHRONIC VIRAL HEPATITIS IN EUROPE Budapest, Hungary, March 18-19, 21 Identification and management of chronic
More informationUpdate on Transfusion- Transmitted Infectious Diseases
Update on Transfusion- Transmitted Infectious Diseases Scott Koepsell MD PhD Associate Professor University of Nebraska Medical Center I have no conflicts of interest to disclose. Global changes and the
More informationViral Hepatitis in Ireland, 2005
Viral Hepatitis in Ireland, 25 Key Points Hepatitis A incidence remained low, with 56 cases notified in 25 The number of hepatitis B notifications continued to increase with 95 cases reported in 25, compared
More informationHIBA ABDALRAHIM Capsca Focal Point Public Health Authority
HIBA ABDALRAHIM Capsca Focal Point Public Health Authority Introduction Definition Symptom Transmission Global situation Local situation Control Content Introduction Yellow fever (YF) is a mosquito-borne
More informationRisk of Infection when travelling South. Liège Crowne Plaza 19/11/2016
Risk of Infection when travelling South Filipom Klik Moerman, de ondertitelstijl Infectiologist. van het model te bewerken Liège Crowne Plaza 19/11/2016 Strongyloides Middle East respiratory syndrome
More informationHBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board
HBV vaccination: Optimizing coverage and efficacy. Alex Vorsters, Pierre Van Damme Viral Hepatitis Prevention Board 2 nd Hepatitis Cure and Eradication Meeting 11 12 November 2015 Declaration of Interest
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More informationInfectious Diseases. Colin R. Howard ( 郝高林 ) Royal Veterinary College University of London ( 伦敦大学皇家兽医学院 )
Infectious Diseases Colin R. Howard ( 郝高林 ) Royal Veterinary College University of London ( 伦敦大学皇家兽医学院 ) The Challenge of Infectious Disease Infectious disease represents the greatest challenge to mankind
More informationAvian Influenza (Bird Flu) Fact Sheet
What is an avian influenza A (H5N1) virus? Influenza A (H5N1) virus also called H5N1 virus is an influenza A virus subtype that occurs mainly in birds. It was first isolated from birds (terns) in South
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young
More informationTechnical matters: Viral hepatitis
REGIONAL COMMITTEE Provisional Agenda item 8.6 Sixty-seventh Session SEA/RC67/29 Dhaka, Bangladesh 9 12 September 2014 28 July 2014 Technical matters: Viral hepatitis Viral hepatitis is a serious public
More informationHuman health effects of aflatoxins
Human health effects of aflatoxins Dr. Martin E. Kimanya Nelson Mandela African Institute of Science and Technology PACA Strategy Development - Stakeholder Consultation Workshop 10-12 April 2013 Health
More informationViral Hepatitis B and C in North African Countries
Viral Hepatitis B and C in North African Countries Prevalence, Risk factors and How to prevent Prof. Ossama Rasslan President, ESIC ICAN, Vice-Chair ICAN 2014, Harare, Zimbabwe, Nov 3rd 5th Overview Viral
More informationFebruary Emerging Infectious Diseases: The Global Picture
Emerging Infectious Diseases: The Global Picture Breaches in species barrier: emerging infections in humans Infection Animal linked Year infection to transmission first reported Ebola virus Bats 1976 HIV-1
More informationPrevention of viral hepatitis in Germany and Scandinavia. Viral Hepatitis Prevention Board Berlin, October 2003
Prevention of viral hepatitis in Germany and Scandinavia Viral Hepatitis Prevention Board Berlin, 13-14 October 2003 Aims and objectives Epidemiological update Review of surveillance systems for infectious
More informationInfectious Disease Outbreaks in confined spaces
Infectious Disease Outbreaks in confined spaces Dr Andrew Ebringer Senior Medical Director, Medical Services - Australia International SOS 1 2013 AEA International Holdings Pte. Ltd. All rights reserved.
More informationIs it the time to start blood screening for Hepatitis-E?
Is it the time to start blood screening for Hepatitis-E? Dr. Somnath Mukherjee MD, MAMS Assistant Professor All India Institute of Medical Sciences Bhubaneswar During last 25 years the safety of blood
More informationGlobal Polio Eradication & Endgame Strategy. December 2015
Global Polio Eradication & Endgame Strategy December 2015 Poliovirus detection & interruption OPV withdrawal, IPV introduction, RI strengthening Containment & Global Certification Legacy Planning Polio
More informationCore 3: Epidemiology and Risk Analysis
Core 3: Epidemiology and Risk Analysis Aron J. Hall, DVM, MSPH, DACVPM CDC Viral Gastroenteritis Team NoroCORE Full Collaborative Meeting, Atlanta, GA November 7, 2012 Core 3: Purpose and Personnel * Purpose:
More information9/12/2018. Hepatitis B Virus Infection. Hepatitis B Infection
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Hepatitis B and Hepatitis B Vaccine Adult Track Chapter 10 Photographs and images included in this presentation
More informationUpdate of hepa++s E in Hong Kong. Dr Chow Chi Wing Department of Medicine Tseung Kwan O Hospital
Update of hepa++s E in Hong Kong Dr Chow Chi Wing Department of Medicine Tseung Kwan O Hospital HEV: The History Probably causing human disease for centuries Iden+fied on EM by Dr Balayan in 1983 Viral
More informationHepatitis B and Hepatitis B Vaccine
Hepatitis B and Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at http://www.vaccineinformation.org/photos/index.asp
More informationEPIDEMIOLOGY OF HEPATITIS A IN IRELAND
EPIDEMIOLOGY OF HEPATITIS A IN IRELAND Table of Contents Acknowledgements 3 Summary 4 Introduction 5 Case Definitions 6 Materials and Methods 7 Results 8 Discussion 10 References 11 Epidemiology of Hepatitis
More informationNew recommendations for immunocompromised patients
New recommendations for immunocompromised patients Hepatitis E Virus (HEV): Transmission, incidence and presentation Emerging evidence regarding HEV transmission from blood components and dietary consumption
More informationImmunization Guidelines for the Use of State Supplied Vaccine April 18, 2013
DTaP / DT DTaP/IPV/Hep B Combination (Pediarix ) Children from 6 weeks of age up to the 7 th birthday Children from 2 months of age up to the 7th birthday: Indicated for the primary doses of DTaP, IPV,
More informationClinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL
Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL The World Health Organisation recent initiatives on HBV infection Launching of the
More informationESCMID Online Lecture Library. by author
Challenges and Controversies in Vaccination TRAVEL VACCINES Resat Ozaras, MD, Professor, Istanbul University Cerrahpasa Medical School Infectious Dis. Dept. Risk of exposure The severity of the disease
More informationImmunization of Adults in High Risk Populations. Carol A. Kurbis MD, CCFP, FRCPC WRHA Medical Officer of Health
Immunization of Adults in High Risk Populations Carol A. Kurbis MD, CCFP, FRCPC WRHA Medical Officer of Health OBJECTIVES To review recommendations for immunization in adult populations, with a focus on
More informationHEV Update Blood Components. Dragoslav Domanović, European Centre for Disease Prevention and Control (Sweden)
HEV Update Blood Components Dragoslav Domanović, European Centre for Disease Prevention and Control (Sweden) Outline ECDC activities started in 2015 to understand the epidemiology and burden of HEV infection
More informationAnnual Tuberculosis Report Oregon 2007
Annual Tuberculosis Report Oregon 7 Oregon Department of Human Services Public Health Division TB Program April 8 Page 2 Table of Contents Charts Chart 1 TB Incidence in the US and Oregon, 1985-7.. page
More informationAcute hepatitis can be a severe disease among. Acute Hepatitis in Israeli Travelers ORIGINAL ARTICLE
I S T M 232 ORIGINAL ARTICLE Acute Hepatitis in Israeli Travelers Tamar Lachish, MD, Moshik Tandlich, DMD, and Eli Schwartz, MD, DTMH The Infectious Diseases Unit, Shaare-Zedek Medical Center, Jerusalem,
More informationPeople left behind: Sex workers
GAP Report 2014 People left behind: Sex workers Link with the pdf, Sex workers I am a sex worker. I face these issues. HIV prevalence among sex workers, 2009 2013 Source: Global AIDS Response Progress
More informationSummary of Key Points
Summary of Key Points WHO Position Paper on Vaccines against Pertussis September 2015 1 Background l Pertussis (whooping cough), caused by the bacterium Bordetella pertussis, was one of the most common
More informationBasic guidelines for promotion of control measures for hepatitis
Basic guidelines for promotion of control measures for hepatitis May 16, 2011 Table of Contents Chapter 1 Basic approach for preventing hepatitis and promoting medical care of hepatitis - 2 - Chapter 2
More informationAdvisory on Plague WHAT IS PLAGUE? 19 October 2017
19 October 2017 Advisory on Plague WHAT IS PLAGUE? Plague is an infectious disease caused by the zoonotic bacteria, Yersinia pestis. This bacteria often infects small rodents (like rats, mice, and squirrels)
More informationNHS public health functions agreement Service specification No.1 Neonatal hepatitis B immunisation programme
NHS public health functions agreement 2017-18 Service specification No.1 Neonatal hepatitis B immunisation programme NHS public health functions agreement 2017-18 Service specification No.1Neonatal hepatitis
More informationImportant Information About Vaccinia (Smallpox) Vaccine Please Read This Carefully
Important Information About Vaccinia (Smallpox) Vaccine Please Read This Carefully Introduction Vaccinia vaccine, previously known as smallpox vaccine, is highly effective in producing immunity to smallpox
More informationDr Suresh Kumar Consultant Infectious Diseases Physician Hospital Sungai Buloh. Influenza Vaccination of Health Care Workers-
Dr Kumar Consultant Infectious Diseases Physician Hospital Sungai Buloh Influenza Vaccination of Health Care Workers- Outline Influenza in the tropics Rationale and purpose of HCW vaccination Efficacy
More informationHepatitis C Best Practice Guidelines For Local Health Departments
Hepatitis C Best Practice Guidelines For Local Health Departments LHDs are responsible for investigating and reporting all physician reported cases of acute hepatitis C (HCV). For clients known to have
More informationClassification: official 1
NHS public health functions agreement 2018-19 Service specification No.4 Immunisation against diphtheria, tetanus, poliomyelitis, pertussis, Hib and HepB programme 1 NHS public health functions agreement
More informationWhy is surveillance important after introducing vaccines?
Why is surveillance important after introducing vaccines? Dr Michael Edelstein Immunisation Department, National Infections service Public Health England @epi_michael BSAC Spring conference, 12 th March
More informationOREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS INACTIVATED JAPANESE ENCEPHALITIS VIRUS VACCINE
OREGON HEALTH AUTHORITY IMMUNIZATION PROTOCOL FOR PHARMACISTS INACTIVATED JAPANESE ENCEPHALITIS VIRUS VACCINE Update as of 06 2010 Addition of IXIARO, Inactivated, Adsorbed vaccine; grown in tissue culture
More informationHepadnaviridae family (DNA) Numerous antigenic components Humans are only known host May retain infectivity for more than 7 days at room temperature
Hepatitis B Epidemic jaundice described by Hippocrates in 5th century BC Jaundice reported among recipients of human serum and yellow fever vaccines in 1930s and 1940s Australia antigen described in 1965
More information